17 June 2021
Vermont Attorney General's Office
109 State Street
Montpelier, VT 05609

RE: New Prescription Drug – 3 Day Notice

Dear Sir or Madam,
In accordance with 18 V.S.A. § 4637, Myovant Sciences, Inc. provides the following notification of introduction of MYFEMBREE® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) whose WAC exceeds the threshold set for a specialty drug under the Medicare Part D program:

NDC	PRODUCT	PACKAGE SIZE
72974-415-01	MYFEMBREE (relugolix 40 mg, estradiol 1 mg and norethindrone acetate 0.5 mg) tablets	28 tablets

Please do not hesitate to contact us if you have any questions.

Regards,

DocuSigned by:
Raymond Wang
7EF4D5010CFD44D...

Raymond Wang
Associate Director, Pricing & Contracting
Myovant Sciences, Inc.

WAC represents the manufacturer's published catalog or list price for a drug product to wholesalers as reported to third-party pricing publishers. WAC does not represent actual transaction prices and does not include discounts, rebates, or reduction in price. Pricing information listed does not imply safety or efficacy of the product, and no comparisons should be made.